Chiariello Giovanni A, Bruno Piergiorgio, Villa Emmanuel, Pasquini Annalisa, Pavone Natalia, Cammertoni Federico, Mazza Andrea, Colizzi Christian, Nesta Marialisa, Iafrancesco Mauro, Perri Gianluigi, Messina Antonio, Troise Giovanni, Massetti Massimo
1 Cardiovascular Sciences Department, Foundation Polyclinic University A. Gemelli IRCCS, Rome, Italy.
2 Catholic University of The Sacred Heart, Rome, Italy.
Innovations (Phila). 2019 Feb;14(1):27-36. doi: 10.1177/1556984519826430. Epub 2019 Mar 7.
Aortic valve replacement (AVR) in patients with small aortic annulus (diameter ≤21 mm) is considered a challenging scenario because of technical aspects and the high risk of patient-prosthesis mismatch (PPM). The choice of the appropriate prosthesis is crucial, and at the moment, an ideal device has yet to be identified. We compare clinical and hemodynamic results after AVR with three bioprostheses with different design and characteristics.
We retrospectively evaluated 76 consecutive patients from two cardiac surgery centers who underwent AVR (Trifecta = 24; Edwards INTUITY Elite valve system = 26, and Perceval = 26) for severe aortic stenosis between 2013 and 2017. Patients selected were older than 75 years and with an annulus diameter ≤21 mm at preoperative echocardiogram. Reinterventions and combined procedures were excluded. Minimally invasive AVR was performed in 44 (57.8%) patients. Telephonic interview was obtained at 2.9 ± 0.5 years and echocardiographic follow-up at 2.2 ± 0.8 years.
Clinical outcome was similar in the three groups. At follow-up, Trifecta patients presented significantly higher peak and mean transprosthetic pressure gradients ( P = 0.04 and 0.01). Effective orifice area and left ventricular mass regression were comparable, although an advantage was observed in Perceval patients without reaching the statistical significance. Incidence of moderate ( P = 0.2) and severe PPM ( P = 0.7) was comparable.
Despite higher postoperative pressure gradients observed with the Trifecta valve, all three prostheses (Trifecta, Edwards INTUITY Elite, and Perceval) have proven to be reliable when implanted in small aortic annuli, with good clinical outcome and favorable left ventricular mass regression.
对于主动脉瓣环较小(直径≤21mm)的患者,主动脉瓣置换术(AVR)因技术方面以及患者-人工瓣膜不匹配(PPM)的高风险而被视为具有挑战性的情况。选择合适的人工瓣膜至关重要,目前尚未确定理想的装置。我们比较了使用三种具有不同设计和特性的生物人工瓣膜进行AVR后的临床和血流动力学结果。
我们回顾性评估了2013年至2017年间来自两个心脏外科中心的76例连续接受AVR(Trifecta = 24例;爱德华兹INTUITY Elite瓣膜系统 = 26例,以及Perceval = 26例)治疗严重主动脉瓣狭窄的患者。入选患者年龄大于75岁,术前超声心动图显示瓣环直径≤21mm。排除再次干预和联合手术。44例(57.8%)患者接受了微创AVR。在2.9±0.5年时进行电话随访,在2.2±0.8年时进行超声心动图随访。
三组的临床结果相似。随访时,Trifecta患者的跨瓣峰值和平均压力梯度显著更高(P = 0.04和0.01)。有效瓣口面积和左心室质量减轻情况相当,尽管在Perceval患者中观察到优势,但未达到统计学意义。中度(P = 0.2)和重度PPM(P = 0.7)的发生率相当。
尽管Trifecta瓣膜术后压力梯度较高,但当植入小主动脉瓣环时所有三种人工瓣膜(Trifecta、爱德华兹INTUITY Elite和Perceval)已被证明是可靠的,具有良好的临床结果和有利的左心室质量减轻。